Minimally invasive pelvic exenteration for primary or recurrent locally advanced rectal cancer: A glimpse into the future.
| Autor: | Kehagias D; Department of General Surgery, General University Hospital of Patras, Patras 26504, Greece. dimikech@gmail.com., Lampropoulos C; Intensive Care Unit, Saint Andrew's General Hospital, Patras 26335, Greece., Kehagias I; Division of Bariatric and Metabolic Surgery, Department of Surgery, University of Patras, Patras 26504, Greece. |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | World journal of gastrointestinal surgery [World J Gastrointest Surg] 2024 Jul 27; Vol. 16 (7), pp. 1960-1964. |
| DOI: | 10.4240/wjgs.v16.i7.1960 |
| Abstrakt: | Surgeons have grappled with the treatment of recurrent and T4b locally advanced rectal cancer (LARC) for many years. Their main objectives are to increase the overall survival and quality of life of the patients and to mitigate postoperative complications. Currently, pelvic exenteration (PE) with or without neoadjuvant treatment is a curative treatment when negative resection margins are achieved. The traditional open approach has been favored by many surgeons. However, the technological advancements in minimally invasive surgery have radically changed the surgical options. Recent studies have demonstrated promising results in postoperative complications and oncological outcomes after robotic or laparoscopic PE. A recent retrospective study entitled "Feasibility and safety of minimally invasive multivisceral resection for T4b rectal cancer: A 9-year review" was published in the World Journal of Gastrointestinal Surgery . As we read this article with great interest, we decided to delve into the latest data regarding the benefits and risks of minimally invasive PE for LARC. Currently, the small number of suitable patients, limited surgeon experience, and steep learning curve are hindering the establishment of minimally invasive PE. Competing Interests: Conflict-of-interest statement: The authors have no conflicts of interest to declare. (©The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved.) |
| Databáze: | MEDLINE |
| Externí odkaz: |
|